939-P: Safety of Newer Glucose Medications in Adults with Type 2 Diabetes and Low to Moderate CV Risk

Introduction Johnson Alexion Pharmaceuticals, Inc. Other Relationship; Wolters Kluwer Health. E.O. DiCesare: None. C. Alix: None. D.J. Wexler: Other Relationship; Novo Nordisk. E. Patorno: Research Support; Boehringer-Ingelheim, Food and Drug Administration (FDA), National Institutes of Health, Patient-Centered Outcomes Research Institute. Funding Patient Centered Outcomes Research Institute (DB-2020C2-20326)